Oppenheimer & CO Inc Exelixis, Inc. Transaction History

Oppenheimer & CO Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$20.34 - $23.73 $272,556 - $317,982	13,400 New	13,400 $301,000
Q2 2021 Aug 03, 2021	SELL	$17.95 - $25.56 $162,034 - $230,730	-9,027 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$20.53 - $25.22 $185,324 - $227,660	9,027 New	9,027 $204,000
Q2 2020 Aug 11, 2020	SELL	$16.46 - $27.42 $453,473 - $755,421	-27,550 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$14.46 - $21.8 $212,778 - $320,787	14,715 Added 114.65%	27,550 $474,000
Q4 2019 Feb 07, 2020	SELL	$15.15 - $18.89 $163,226 - $203,520	-10,774 Reduced 45.64%	12,835 $226,000
Q3 2019 Oct 31, 2019	SELL	$17.68 - $22.65 $56,151 - $71,936	-3,176 Reduced 11.86%	23,609 $417,000
Q2 2019 Aug 09, 2019	SELL	$18.93 - $24.75 $142,505 - $186,318	-7,528 Reduced 21.94%	26,785 $572,000
Q1 2019 Apr 24, 2019	BUY	$19.6 - $24.76 $226,634 - $286,299	11,563 Added 50.83%	34,313 $816,000
Q4 2018 Jan 29, 2019	BUY	$13.65 - $21.8 $30,971 - $49,464	2,269 Added 11.08%	22,750 $447,000
Q3 2018 Oct 26, 2018	SELL	$15.87 - $22.4 $137,307 - $193,804	-8,652 Reduced 29.7%	20,481 $363,000
Q2 2018 Aug 10, 2018	BUY	$18.56 - $22.45 $204,104 - $246,882	10,997 Added 60.64%	29,133 $627,000
Q1 2018 May 01, 2018	SELL	$22.15 - $31.89 $102,111 - $147,012	-4,610 Reduced 20.27%	18,136 $402,000
Q4 2017 Feb 07, 2018	BUY	$24.23 - $30.93 $551,135 - $703,533	22,746	22,746 $691,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.